RBP-J INHIBITION AS A NOVEL LATENCY REVERSAL STRATEGY FOR HIV-1-RELATED KIDNEY DISEASES
$1,550,000FY2025Defense Health AgencyDOD
University Of Kansas Medical Center Research Institute, Inc.
University Of Kansas Medical Center Research Institute, Inc.